283 related articles for article (PubMed ID: 34996423)
1. Cost-effectiveness and health impact of lung cancer screening with low-dose computed tomography for never smokers in Japan and the United States: a modelling study.
Kowada A
BMC Pulm Med; 2022 Jan; 22(1):19. PubMed ID: 34996423
[TBL] [Abstract][Full Text] [Related]
2. Risk-Targeted Lung Cancer Screening: A Cost-Effectiveness Analysis.
Kumar V; Cohen JT; van Klaveren D; Soeteman DI; Wong JB; Neumann PJ; Kent DM
Ann Intern Med; 2018 Feb; 168(3):161-169. PubMed ID: 29297005
[TBL] [Abstract][Full Text] [Related]
3. Estimating the Cost-Effectiveness of Lung Cancer Screening with Low-Dose Computed Tomography for High-Risk Smokers in Australia.
Wade S; Weber M; Caruana M; Kang YJ; Marshall H; Manser R; Vinod S; Rankin N; Fong K; Canfell K
J Thorac Oncol; 2018 Aug; 13(8):1094-1105. PubMed ID: 29689434
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.
Jaine R; Kvizhinadze G; Nair N; Blakely T
Lung Cancer; 2018 Oct; 124():233-240. PubMed ID: 30268467
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Low-Dose Computed Tomography With a Plasma-Based Biomarker for Lung Cancer Screening in China.
Zhao Z; Wang Y; Wu W; Yang Y; Du L; Dong H
JAMA Netw Open; 2022 May; 5(5):e2213634. PubMed ID: 35608858
[TBL] [Abstract][Full Text] [Related]
6. Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation.
Snowsill T; Yang H; Griffin E; Long L; Varley-Campbell J; Coelho H; Robinson S; Hyde C
Health Technol Assess; 2018 Nov; 22(69):1-276. PubMed ID: 30518460
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers: a microsimulation modelling study.
Du Y; Sidorenkov G; Heuvelmans MA; Groen HJM; Vermeulen KM; Greuter MJW; de Bock GH
Eur J Cancer; 2020 Aug; 135():121-129. PubMed ID: 32563896
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study.
Criss SD; Cao P; Bastani M; Ten Haaf K; Chen Y; Sheehan DF; Blom EF; Toumazis I; Jeon J; de Koning HJ; Plevritis SK; Meza R; Kong CY
Ann Intern Med; 2019 Dec; 171(11):796-804. PubMed ID: 31683314
[TBL] [Abstract][Full Text] [Related]
9. Low-dose chest computed tomography for lung cancer screening among Hodgkin lymphoma survivors: a cost-effectiveness analysis.
Wattson DA; Hunink MG; DiPiro PJ; Das P; Hodgson DC; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):344-53. PubMed ID: 25104066
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of screening for lung cancer with low-dose computed tomography: a systematic literature review.
Puggina A; Broumas A; Ricciardi W; Boccia S
Eur J Public Health; 2016 Feb; 26(1):168-75. PubMed ID: 26370440
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of CT screening in the National Lung Screening Trial.
Black WC; Gareen IF; Soneji SS; Sicks JD; Keeler EB; Aberle DR; Naeim A; Church TR; Silvestri GA; Gorelick J; Gatsonis C;
N Engl J Med; 2014 Nov; 371(19):1793-802. PubMed ID: 25372087
[TBL] [Abstract][Full Text] [Related]
12. Lung cancer screening with low-dose computed tomography: National expenditures and cost-effectiveness.
Zeng X; Zhou Z; Luo X; Liu Q
Front Public Health; 2022; 10():977550. PubMed ID: 36249202
[TBL] [Abstract][Full Text] [Related]
13. Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations.
Behr CM; Oude Wolcherink MJ; IJzerman MJ; Vliegenthart R; Koffijberg H
Pharmacoeconomics; 2023 Apr; 41(4):395-411. PubMed ID: 36670332
[TBL] [Abstract][Full Text] [Related]
14. A cost-effectiveness analysis of lung cancer screening with low-dose computed tomography and a polygenic risk score.
Zhao Z; Gu S; Yang Y; Wu W; Du L; Wang G; Dong H
BMC Cancer; 2024 Jan; 24(1):73. PubMed ID: 38218803
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of the introduction of low-dose CT screening in Japanese smokers aged 55 to 74 years old.
Tabata H; Akita T; Matsuura A; Kaishima T; Matsuoka T; Ohisa M; Awai K; Tanaka J
Hiroshima J Med Sci; 2014 Sep; 63(1-3):13-22. PubMed ID: 25735063
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of Lung Cancer Screening in Canada.
Goffin JR; Flanagan WM; Miller AB; Fitzgerald NR; Memon S; Wolfson MC; Evans WK
JAMA Oncol; 2015 Sep; 1(6):807-13. PubMed ID: 26226181
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analyses of Lung Cancer Screening Strategies Using Low-Dose Computed Tomography: a Systematic Review.
Raymakers AJN; Mayo J; Lam S; FitzGerald JM; Whitehurst DGT; Lynd LD
Appl Health Econ Health Policy; 2016 Aug; 14(4):409-418. PubMed ID: 26873091
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of baseline low-dose computed tomography screening for lung cancer: the Israeli experience.
Shmueli A; Fraifeld S; Peretz T; Gutfeld O; Gips M; Sosna J; Shaham D
Value Health; 2013; 16(6):922-31. PubMed ID: 24041342
[TBL] [Abstract][Full Text] [Related]
19. Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada.
Ten Haaf K; Tammemägi MC; Bondy SJ; van der Aalst CM; Gu S; McGregor SE; Nicholas G; de Koning HJ; Paszat LF
PLoS Med; 2017 Feb; 14(2):e1002225. PubMed ID: 28170394
[TBL] [Abstract][Full Text] [Related]
20. A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions.
Villanti AC; Jiang Y; Abrams DB; Pyenson BS
PLoS One; 2013; 8(8):e71379. PubMed ID: 23940744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
